Is the fluoroquinolone combination necessary for empirical antibiotic regimen in severe community-acquired pneumonia?

References

• Corrales-Medina VF, Suh KN, Rose G, et al. Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies. PLOS Med. 2011;8(6):e1001048. doi: 10.1371/journal.pmed.1001048
   PubMed Web of Science ®Google Scholar
• Lee KH. Patient stratification and decision to hospitalize patients with community-acquired pneumonia. J Korean Med Assoc. 2007;50(10):868–876. doi: 10.5124/jkma.2007.50.10.868
   Google Scholar
• Korea National Statistical Office. Cause-of-death statistics. Annual report on the cause of death statistics 2021. Nationwide. 2022. Available from: https://kostat.go.kr/board.es?mid=a10301010000&bid=218&tag=&act=view&list_no=420715&ref_bid=
   Google Scholar
• Lee MS, Oh JY, Kang CI, et al. Guideline for antibiotic use in adults with community-acquired pneumonia. Infect Chemother. 2018;50(2):160–198. doi: 10.3947/ic.2018.50.2.160
   PubMed Web of Science ®Google Scholar
• Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America; American Thoracic Society. Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(suppl 2):S27–S72. doi: 10.1086/511159
   PubMed Web of Science ®Google Scholar
• Chong YP, Jung KS, Lee KH, et al. The bacterial etiology of community-acquired pneumonia in Korea: a nationwide prospective multicenter study. Infect Chemother. 2010;42(6):397–403. doi: 10.3947/ic.2010.42.6.397
   Google Scholar
• Jeon EJ, Cho SG, Shin JW, et al. The difference in clinical presentation between healthcare-associated and community-acquired pneumonia in university-affiliated hospital in Korea. Yonsei Med J. 2011;52(2):282–287. doi: 10.3349/ymj.2011.52.2.282
   PubMed Web of Science ®Google Scholar
• Kang YS, Ryoo SR, Byun SJ, et al. Antimicrobial resistance and clinical outcomes in nursing home-acquired pneumonia, compared to community-acquired pneumonia. Yonsei Med J. 2017;58(1):180–186. doi: 10.3349/ymj.2017.58.1.180
   PubMed Web of Science ®Google Scholar
• Seo HW, Cha SI, Shin KM, et al. Clinical relevance of necrotizing change in patients with community-acquired pneumonia. Respirology. 2017;22(3):551–558. doi: 10.1111/resp.12943
   PubMed Web of Science ®Google Scholar
• Spellberg B, Guidos R, Gilbert D, et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the infectious diseases society of America. Clin Infect Dis. 2008;46(2):155–164. doi: 10.1086/524891
   PubMed Web of Science ®Google Scholar
• Livermore DM. Current epidemiology and growing resistance of gram-negative pathogens. Korean J Intern Med. 2012;27(2):128–142. doi: 10.3904/kjim.2012.27.2.128
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi: 10.1016/0021-9681(87)90171-8
   PubMedGoogle Scholar
• Arancibia F, Bauer TT, Ewig S, et al. Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med. 2002;162(16):1849–1858. doi: 10.1001/archinte.162.16.1849
   PubMedGoogle Scholar
• von Baum H, Welte T, Marre R, et al. Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors. Eur Respir J. 2010;35(3):598–615. doi: 10.1183/09031936.00091809
   PubMed Web of Science ®Google Scholar
• Restrepo MI, Babu BL, Reyes LF, et al. Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients. Eur Respir J. 2018;52(2):1701190. doi: 10.1183/13993003.01190-2017
   PubMed Web of Science ®Google Scholar
• Zhydkov A, Christ-Crain M, Thomann R, et al. Utility of procalcitonin, C-reactive protein and white blood cells alone and in combination for the prediction of clinical outcomes in community-acquired pneumonia. Clin Chem Lab Med. 2015;53(4):559–566. doi: 10.1515/cclm-2014-0456
   PubMed Web of Science ®Google Scholar
• Kruger S, Ewig S, Papassotiriou J, et al. Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP – results from the German competence network CAPNETZ. Respir Res. 2009;10(1):65. doi: 10.1186/1465-9921-10-65
   PubMedGoogle Scholar
• Cilloniz C, Gabarrus A, Ferrer M, et al. Community-acquired pneumonia due to multidrug- and non–multidrug-resistant Pseudomonas aeruginosa. Chest. 2016;150(2):415–425. doi: 10.1016/j.chest.2016.03.042
   PubMed Web of Science ®Google Scholar
• Bruns AH, Oosterheert JJ, Hak E, et al. Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia. Eur Respir J. 2008;32(3):726–732. doi: 10.1183/09031936.00003608
   PubMed Web of Science ®Google Scholar
• Kim HJ, Oh DK, Lim SY, et al. Antibiogram of multidrug-resistant bacteria based on sepsis onset location in Korea: a multicenter cohort study. J Korean Med Sci. 2023;38(10):e75. doi: 10.3346/jkms.2023.38.e75
   PubMed Web of Science ®Google Scholar
• Tandan M, Cormican M, Vellinga A. Adverse events of fluoroquinolones vs. other antimicrobials prescribed in primary care: a systematic review and meta-analysis of randomized controlled trials. Int J Antimicrob Agents. 2018;52(5):529–540. doi: 10.1016/j.ijantimicag.2018.04.014
   PubMed Web of Science ®Google Scholar
• Kuye O, Teal J, DeVries VG. Safety profile of piperacillin/tazobactam in phase I and III clinical studies. J Antimicrob Chemother. 1993;31(Suppl A):113–124. doi: 10.1093/jac/31.suppl_a.113
   PubMed Web of Science ®Google Scholar
• Scheetz MH, McKoy JM, Parada JP, et al. Systematic review of piperacillin-induced neutropenia. Drug Saf. 2007;30(4):295–306. doi: 10.2165/00002018-200730040-00002
   PubMed Web of Science ®Google Scholar
• Rider AC, Frazee BW. Community-acquired pneumonia. Emerg Med Clin North Am. 2018;36(4):665–683. doi: 10.1016/j.emc.2018.07.001
   PubMed Web of Science ®Google Scholar
• Shindo Y, Ito R, Kobayashi D, et al. Risk factors for 30-day mortality in patients with pneumonia who receive appropriate initial antibiotics: an observational cohort study. Lancet Infect Dis. 2015;15(9):1055–1065. doi: 10.1016/S1473-3099(15)00151-6
   PubMed Web of Science ®Google Scholar
• Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA. 1996;275(2):134–141.
   PubMed Web of Science ®Google Scholar
• Garin N, Genne D, Carballo S, et al. β-Lactam Monotherapy vs β-Lactam–Macrolide combination treatment in moderately severe community-acquired pneumonia. JAMA Intern Med. 2014;174(12):1894–1901. doi: 10.1001/jamainternmed.2014.4887
   PubMed Web of Science ®Google Scholar
• Martin-Loeches I, Lisboa T, Rodriguez A, et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive care Med. 2010;36(4):612–620. doi: 10.1007/s00134-009-1730-y
   PubMed Web of Science ®Google Scholar
• Chen YC, Lu PL, Lin CY, et al. Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systematic review and meta-analysis. Int J Infect Dis. 2011;15(3):e211–6. doi: 10.1016/j.ijid.2010.11.008
   PubMed Web of Science ®Google Scholar
• Tanne JH. FDA adds “black box” warning label to fluoroquinolone antibiotics. BMJ. 2008;337(jul15 1):a816. doi: 10.1136/bmj.a816
   PubMedGoogle Scholar